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A B S T R A C T
Purpose: Edaravone (MCI-186) is a newly developed antioxidative radical scavenger for the treatment of
acute cerebral infarction, exerting neuroprotective effects against ischemic insult. The neuroprotective
effects of edaravone on pilocarpine-induced seizures in rats were investigated.
Methods: Rats were treated intraperitoneally with saline or edaravone (1–30 mg/kg), applied 30 min
before pilocarpine hydrochloride (330 mg/kg). The onset of status epilepticus (SE) and mortality were
recorded for a period of at least 3 days. The cell loss and immunoreactivities of nitric oxide synthase (NOS)
in the hippocampus from control and the day 3 rats after SE, treated with saline or edaravone, were
evaluated.
Results: Edaravone (1 mg/kg) signiﬁcantly prevented cell loss in the hippocampus after SE while easier
inducing SE. The higher dose of drug could not induce SE signiﬁcantly but tended to increase the rate of
mortality. Inducible NOS (iNOS) expression was signiﬁcantly decreased in the hippocampus from day 3
rats treated with 1 mg/kg edaravone, compared with saline group, while neuronal NOS (nNOS) and iNOS
signiﬁcantly increased in the hippocampus treated with saline, compared with control group. Signiﬁcant
alteration of endothelial NOS (eNOS) expression in the hippocampus among control group, saline group,
and edaravone group was not shown.
Conclusions: Edaravone may act as a neuroprotector for the hippocampus after SE by reducing at least
iNOS although the low dose of drug easier induces SE because of preventing an endogenous antiepileptic
effect of NO.
Crown Copyright  2008 Published by Elsevier Ltd on behalf of BEA Trading Ltd. All rights reserved.
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Pilocarpine-induced epilepsy rodent models have been fre-
quently used to investigate underlying mechanisms of human
temporal lobe epilepsy (TLE).3,10,11,14,16 Pilocarpine treatment
provokes long-lasting status epilepticus (SE) in the animals. The
animals have spontaneous recurrent seizures after a latent seizure-
free phase characterized by development of hippocampal damage.
Some studies have suggested that free radicals such as nitric oxide
(NO) which is synthesized from arginine by NO synthase (NOS)
plays a crucial role in the above pathogenesis.3,10,11,14,16
Edaravone (MCI-186) is a novel radical scavenger that protects
neurons by inhibiting vascular endothelial cell injury and by
ameliorating neuronal damage caused by acute brain ischemia.18–
20 Edaravonewas found to have antioxidant effects, quenching OH
and inhibiting both OH-dependent and OH-independent lipid
peroxidation, and to exert inhibitory effects on both water-soluble* Corresponding author. Tel.: +81 97 586 5862; fax: +81 97 586 5869.
E-mail address: kamida@med.oita-u.ac.jp (T. Kamida).
1059-1311/$ – see front matter . Crown Copyright  2008 Published by Elsevier Ltd on
doi:10.1016/j.seizure.2008.06.012and lipid-soluble peroxyl radical-induced peroxidation sys-
tems.18–20 Furthermore, edaravone had antioxidant activities,
quenching not only OH but also other free radical species such
as superoxide and NO radicals.18–20 Recent results indicate that
edaravone exerted neuroprotective effects by reducing both
neuronal NOS (nNOS) and inducible NOS (iNOS) and increasing
endothelial NOS (eNOS) in acute ischemia rodent models.13,20,22
However, the possibility that edaravone might have neuroprotec-
tive effects on hippocampal damage in pilocarpine-induced
seizures has not yet been studied.
In the present study, we investigated the neuroprotective
effects of edaravone on pilocarpine-induced seizures in rats
and NOS expression alterations in the hippocampus of the
animals.
2. Methods
Adult male Wistar rats (200–250 g) were housed individually
and kept on a 12-h light/dark cycle. All experimental manipula-
tions were conducted in accordance with the guidelines of Oita
University Animal Care Committee.behalf of BEA Trading Ltd. All rights reserved.
Fig. 1. Bar graphs show the averaged hippocampal neuron densities from the
control and day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg.
The neurons in all hippocampal subﬁelds from the rats treated with PIL/saline were
signiﬁcantly decreased comparedwith those of the control while CA1 neurons from
the rats treatedwith PIL/edaravone 1 mg/kgwere signiﬁcantly decreased compared
with those of the control; *P < 0.05 and **P < 0.01 (Student’s t-test). Error bars
indicate the mean  S.E.M.
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bromide (1 mg/kg s.c.). Five rats received saline i.p. and no
pilocarpine hydrochloride (PIL) (control group). One hundred and
ﬁfty rats received PIL (330 mg/kg i.p.), of which 41 were treated
with saline (PIL/saline group) and 109 with different doses of
edaravone (1, 3, 10, and 30 mg/kg i.p.) (n = 25, 28, 28, and 28). After
40 min, SE was terminated by the injection of diazepam (4 mg/kg
i.p.). All animals including the control were observed for a period of
at least 3 days after the injection of PIL.
Five rats in PIL/saline group, 5 in PIL/edaravone 1 mg/kg group,
1 in PIL/edaravone 10 mg/kg group and 1 in PIL/edaravone 30 mg/
kg group were alive 3 days after SE. The rats which survived were
deeply anesthetized with an overdose of sodium pentobarbital i.p.
and sequentially perfused transcardially with 4% paraformalde-
hyde. Brains were removed and cut en bloc in the coronal plane,
and embedded in parafﬁn.
The 3-mm thick coronal sections through the hippocampus
were stained with hematoxylin and eosin as a counterstain and
then stained immunohistochemically using the labeled streptoa-
vidin-biotin method (Dako Lab Kit, Dako, Kyoto, Japan) atFig. 2. Immunohistochemical staining for nNOS in the hippocampus from day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. nNOS expression was not
increased in the hippocampus from a rat treated with PIL/edaravone 1 mg/kg while it was slightly increased in the hippocampus from a rat treated with PIL/saline, compared
with a control.
Table 1
Effect of pretreatment with edaravone on seizures induced by pilocarpine
Dose of edaravone (mg/kg) n Status epilepticus Latency (s) to status epilepticus (mean  S.E.M.) Mortalitya (<2 h)
0 (saline) 41 14/41 (34%) 20.1  2.2 9/14 (64%)
1 25 17/25 (68%)* 27.6  2.8 12/17 (71%)
3 28 12/28 (43%) 23.6  4.9 9/12 (75%)
10 28 13/28 (46%) 24.2  2.8 10/13 (77%)
30 28 11/28 (39%) 22.5  3.3 9/11 (81%)
a In rats with status epilepticus.
* P < 0.05 vs. non-administration of edaravone group, Fisher’s exact test.
Fig. 3. Immunohistochemical staining for iNOS in thehippocampus fromday3 rats after SE, treatedwithPIL/salineorPIL/edaravone1 mg/kg. iNOSexpressionwasnot increased in
the hippocampus from a rat treatedwith PIL/edaravone 1mg/kgwhile it wasmarkedly increased in the hippocampus from a rat treatedwith PIL/saline, comparedwith a control.
Fig. 4. Immunohistochemical staining for eNOS in the hippocampus fromday3 rats after SE, treatedwithPIL/salineorPIL/edaravone 1 mg/kg. eNOSexpressionwasnot increased
in the hippocampus from a rat treated with PIL/edaravone 1 mg/kg while it was little increased in the hippocampus from a rat treated with PIL/saline, compared with a control.
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Fig. 5.NOS intensity score in the hippocampus from the control and day 3 rats after
SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. iNOS expression was
signiﬁcantly decreased in the hippocampus from day 3 rats treated with PIL/
edaravone 1 mg/kg, comparedwith saline group, while nNOS and iNOS signiﬁcantly
increased in the hippocampus treated with PIL/saline, compared with control
group. Signiﬁcant alteration of endothelial NOS (eNOS) expression in the
hippocampus among control group, PIL/saline group, and PIL/edaravone group
was not shown; **P < 0.01 and #P < 0.05 (Wilcoxon signed rank test). Error bars
indicate the mean  S.E.M.
T. Kamida et al. / Seizure 18 (2009) 71–7574designated times (control, 1 and 3 days from SE). The following
primary antibodieswere used: rabbit polyclonal antibodies against
human brain neuronal NOS (nNOS:CHM, CA, USA; dilution 1:2500–
5000), inducible NOS (iNOS:BOX, CA, USA; dilution 1:1000), and
endothelial NOS (eNOS:ABR, CO, USA; dilution 1:100).
Cells numbers were counted in different hippocampal subﬁelds
(dentate gyrus, Hilus, CA1, and CA3) of the dorsal hippocampus in
control, rats treated with PIL/saline, and rats with PIL/edaravone.
Quantiﬁcation was performed at 400 magniﬁcation with an
ocular grid (100 boxes of 2.5mm  2.5mm) after two ﬁelds were
randomly selected in the same section. Statistical signiﬁcance of
differences from control was determined by analysis of Fisher’s
exact tests in SE induction andmortality, one-wayANOVA on ranks
in latency to SE and Student’s t-test in cell loss in the hippocampus.
From control, rats treated with PIL/saline, and rats with PIL/
edaravone we evaluated immunoreactivities of nNOS, iNOS, and
eNOS in the different subﬁelds (dentate gyrus, Hilus, CA1, and CA3)
of dorsal hippocampus according to four grades staining score: no
staining 0, slight staining 1, moderate staining 2, or dense staining
3. Statistical signiﬁcance of difference between control group and
PIL/saline group, or between PIL/saline group and PIL/edaravone
groupwere determined by analysis ofWilcoxon signed rank test. A
value of p < 0.05 was considered as signiﬁcant, and p < 0.01 as
highly signiﬁcant.
3. Results
Animals treated with PIL/edaravone 1 mg/kg showed a
signiﬁcantly higher incidence of SE than those treated with PIL/
saline. The rats treated with PIL/higher-dose edaravone revealed
no signiﬁcant difference in incidence of SE compared with those
treated with PIL/saline (Table 1). Edaravone exerts an dose-
dependant increase in the rate of mortality, while showing no
signiﬁcant proconvulsant effect in doses higher than 1 mg/kg
(Table 1). The latency to SE induced by PIL is increased in
edaravone treated rats. There was no signiﬁcant difference in
latency between PIL/edaravone group and PIL/saline group
(Table 1). As well as control (n = 5), rats that were alive 3 days
after SE, treated with PIL/saline (n = 5) or PIL/edaravone 1 mg/kg
(n = 5), were selected for data analysis of cell loss and NOS
expression in the hippocampus.
It was only CA1 neurons from the day 3 rats after SE, treated
with PIL/edaravone 1 mg/kg, that were signiﬁcantly decreased,
compared with those of the control while neurons in all
hippocampal subﬁelds from the day 3 rats after SE, treated with
PIL/saline, were signiﬁcantly decreased, comparedwith the control
(Fig. 1).
nNOS expressionwas signiﬁcantly increased in the CA3 neurons
from day 3 rats after SE, treatedwith PIL/saline, comparedwith the
control (p < 0.01) (Figs. 2 and 5). iNOS expression was signiﬁcantly
increased in the Hilus, CA3, and CA1 neurons from day 3 rats after
SE, treated with PIL/saline, compared with the control (p < 0.01)
(Figs. 3 and 5). The day 3 rats treated with PIL/edaravone 1 mg/kg
showed signiﬁcant decreased expression of iNOS in the Hilus and
CA3 than those treated with PIL/saline (p < 0.05) (Figs. 3 and 5).
Signiﬁcant alteration of eNOS expression in the hippocampus
among control group, PIL/saline group, and PIL/edaravone group
was not shown (Figs. 4 and 5).
4. Discussion
NO is generated from L-arginine andmolecular oxygen by three
NOS isoforms.1,9 Some reports have showed differential roles of
NOS isoforms in the pathogenesis for brain ischemia.6,7,15,21 nNOS-
and iNOS-derived NO is harmful during acute brain ischemia2,5,9,13while eNOS-derived NO plays a protective role, helping to preserve
blood ﬂow.9,13 Recent studies indicated that edaravone exerts
neuroprotective effects by reducing both nNOS and iNOS and by
increasing eNOS in acute ischemia rodent models.13,20,22 In the
similar mechanism, the efﬁcacy of edaravone for brain and spinal
cord injury has also been reported.4,12,17 The present study is a ﬁrst
report showing that edaravone has neuroprotective effects on
hippocampal damage after SE. Our results showed that edaravone
had neuroprotective effects on the rat hippocampus after
pilocarpine-induced SE by reducing at least iNOS though the
low dose of drug easier induced SE.
The neuroprotective effects of edaravone which were indicated
in this study may result especially from iNOS reduction but
probably has no relation with eNOS alteration directly. The low
dose of edaravone may be unable to increase eNOS expression in
the hippocampus after SE.
T. Kamida et al. / Seizure 18 (2009) 71–75 75The previous studies have demonstrated that NOS inhibitors
acting on both nNOS and eNOS have proconvulsant.3,10,16 It was
speculated that proconvulsant effects of NOS inhibition are
associated with the failure of a retrograde inhibition exerted by
NO on NMDA receptors. The low dose of edaravone may easier
induce SE because it makes the retrograde inhibition by NO cease
to exert. On the other hand, eNOS induced by higher dose of
edaravone, which is reported to have anticonvulsant effects,8 may
make it hard to induce SE. However, if SE begins once, it may be
repeated many times because the retrograde inhibition by NO
cannot exert entirely.
Our new data suggests that edaravone probably has neuropro-
tective effects onhumanbrain after SE, but for thepurpose of clinical
use, it should be studied whether the drug has neuroprotective
effects without induction of SE in doses less than 1 mg/kg.
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